“We are speeding up distribution of IFN-β-1a in Singapore for COVID-19 management”
BioSpectrum Asia|BioSpectrum Asia September 2020
We're offering this story for free to read so that you can stay updated on the COVID-19 outbreak
“We are speeding up distribution of IFN-β-1a in Singapore for COVID-19 management”
One of the first companies to partner with Gilead to manufacture remdesivir for COVID-19 treatment, Singapore headquartered SRS Life Sciences is currently working on multiple projects to combat this pandemic. Suchet Rastogi, Chief Executive Officer, SRS Life Sciences spoke to BioSpectrum Asia and revealed the major steps being taken by the company currently. Edited excerpts;
Dr Manbeena Chawla

How is the company contributing to the fight against COVID-19 within Asia and outside?

articleRead

You can read up to 3 premium stories before you subscribe to Magzter GOLD

Log in, if you are already a subscriber

GoldLogo

Get unlimited access to thousands of curated premium stories, newspapers and 5,000+ magazines

READ THE ENTIRE ISSUE

BioSpectrum Asia September 2020